View printer-friendly version |
Charles River Laboratories Selected for 2019 Bloomberg Gender-Equality Index
The 2019 Gender-Equality Index highlights 230 firms that are trailblazers in their commitment to gender diversity in the workplace
Increasing Transparency in Gender Equality
Bloomberg’s standardized reporting framework offers public companies the opportunity to disclose information on how they promote gender equality across four separate areas – company statistics, policies, community engagement and products and services. Reporting companies that score above a globally-established threshold, based on the extent of disclosures and the achievement of best-in-class statistics and policies, are included in the GEI. Still, currently only 10% of eligible companies are disclosing their workplace gender policies and practices.
Approved Quotes
- “I am proud that Charles River was recognized in Bloomberg’s Gender-Equality Index. In 2018, 61 percent of employees promoted and 59 percent of new hires at Charles River were women, which demonstrates our commitment to gender equality. I am personally committed to creating an environment for all employees to have a rewarding and successful career and we have significantly invested in initiatives to ensure Charles River is an employer of choice.” –James C. Foster, Chairman, President and Chief Executive Officer of Charles River
-
“We applaud Charles River and the other 229 firms tracked by the index
for their action to measure gender equality through the Bloomberg GEI
framework. Charles River’s GEI inclusion is a strong indicator to its
employees, investors and industry peers alike that it is leading by
example to advance ongoing efforts for a truly inclusive workplace.”
–Peter T. Grauer, Chairman of
Bloomberg and Founding Chairman of the U.S. 30% Club
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190116005195/en/
Source:
Investor Contact:
Todd Spencer
Corporate Vice
President, Investor Relations
781-222-6455
todd.spencer@crl.com
Media Contacts:
Amy Cianciaruso
Corporate Vice
President, Public Relations,
781-222-6168
amy.cianciaruso@crl.com